v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

COMPARISON OF EFFICACY OF NORTRIPTYLINE AND PROPRANOLOL USED AS MONOTHERAPY AND IN COMBINATION FOR MIGRAINE PROPHYLAXIS

AUTHORS:

Faheem Saeed, Zahid Bashir, Fiaz Hussain

ABSTRACT:

Background: Migraine headache is one of the most common and disabling disorders of nervous system that impairs the quality of life. Combination of nortriptyline and propranolol can be effective in prophylaxis of migraine. Objective: Our aim was to compare the efficacy of nortriptyline and propranolol used as monotherapy and in combination in terms of reduction of number of attacks and duration of pain of migraine. Subjects and Methods: This cross-sectional study was carried out at outpatient clinic, Neurology department, Sir Ganga Ram hospital Lahore from May 2018 to December 2018. Data was collected from 60 patients (15-50 years of age) who fulfilled the diagnostic criteria of migraine using non-probability consecutive sampling technique. They were divided into three groups of 20 patients each. Group A received nortriptyline, group B propranolol and group C combination of both drugs. Results: In group A after three months 8 patients (40%), and after 6 months 12 patients (60%), in group B after three months 7 patients (35%) and after 6 months 11 patients (55%) and in group C at three months 12 patients (60%),at 6 months 16 patients(80%) have 50% or more reduction in number of migraine attacks per month. Similarly, there was significant reduction in duration of pain in group C as compared to group A and B. Conclusion: The efficacy of nortriptyline and propranolol in combination is significantly greater than used as monotherapy in terms of reduction of number of migraine attacks and duration of pain. Keywords: Migraine prophylaxis, nortriptyline, propranolol.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.